AUS
NZ
UK
CA
USA
IND
Highlights
- Cardiol Therapeutics revealed promising results from its Phase II MAvERIC-Pilot study using CardiolRx for recurrent pericarditis treatment.
- Findings from the 26-week trial indicated notable improvements in pain, inflammation, and recurrence rates.
- These results support the progression to advanced clinical trials, including Phase II/III MAVERIC-2 and Phase III MAVERIC-3.
Cardiol Therapeutics (TSX:CRDL), operating in the biotechnology sector, focuses on developing therapies targeting inflammatory and fibrotic conditions. Its primary candidate, CardiolRx, is a cannabidiol-based formulation designed for managing recurrent pericarditis, a painful inflammation of the pericardium.
MAvERIC-Pilot Study Overview
The Phase II MAvERIC-Pilot study was conducted to evaluate the impact of CardiolRx on patients with symptomatic recurrent pericarditis. This trial presented significant findings at the American Heart Association Scientific Sessions 2024, underscoring reductions in pain and inflammation markers over the 26-week study period.
Key Outcomes of the Study
Participants in the study experienced significant improvements in both clinical and biochemical indicators of pericarditis. Pain scores, a critical metric, showed consistent improvement from the initial eight weeks through the trial's conclusion. Inflammation markers normalized in a majority of participants, suggesting the therapy's sustained effect.
Additionally, the frequency of pericarditis episodes declined sharply during the study, with many participants remaining symptom-free after tapering off conventional treatments. Rapid pain relief within the initial days of therapy initiation highlighted the formulation's effectiveness.
Advancing Clinical Trials
Building on the success of the pilot study, Cardiol Therapeutics has initiated and planned further trials. The MAVERIC-2 Phase II/III trial and the MAVERIC-3 Phase III trial aim to explore the broader application of CardiolRx. These trials focus on reducing the recurrence of pericarditis while minimizing the reliance on immunosuppressive therapies.
Focus on Unmet Needs
CardiolRx aims to provide an alternative therapeutic pathway for patients facing limited treatment options. By addressing inflammation without immunosuppression, the therapy is positioned to benefit diverse segments of the pericarditis patient population.
Cardiol Therapeutics continues to advance its clinical programs, striving to improve the quality of life for individuals dealing with this challenging condition.
